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The effect of vitamin D supplementation on the size of 
uterine leiomyoma in women with vitamin D deficiency 
 
Abstract 
Background: Uterine leiomyomas (fibroids) are the most common benign pelvic tumors in 
women of reproductive age with an incidence ranging from 5.4% to 77%, Also, there is a 
high prevalence of vit D deficiency in Iran and there are the numbers of in vivo and vitro 
biological studies on the relationship of vitamin D and uterine leiomyomas
.
 The aim of this 
study was to evaluate the effect of vit D supplementation on the size of uterine leiomyoma 
in women with vit D deficiency. 
Methods: This double-blind prospective clinical trial was performed on 69 patients with 
uterine leiomyomas who had vit D deficiency. Group A (n=35) was treated with vit D 
50,000 IU every 2 weeks for 10 weeks, while group B (n=34) received placebo with same 
color and shape. Finally, the leiomyoma size in both groups was compared (IRCT: 
20160521027998N5). 
Results: After a 10-week intervention, 25-hydroxyvitamin D3 levels were significantly 
higher in group receiving vitamin D (36.08 vs 16.25 ng/ml). (P<0.001) Leiomyomas size 
in vit D group significantly decreased as compared to placebo group (52.58 vs 61.11 mm, 
respectively). 
Conclusion: Our results showed that administration of vit D3 may reduce the size of 
leiomyoma. It seems that vitamin D administration is the effective way to treat leiomyoma. 
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Uterine leiomyomas (fibroids) are the most common benign pelvic tumors in women 
of reproductive age with an incidence ranging from 5.4% to 77%, which grow in the 
uterine muscle of premenopausal women (1, 2). African American race, nulliparity, 
obesity, and a positive family history of fibroids are the risk factors for high rate of 
leiomyoma (3, 4). They may be asymptomatic or can cause abnormal bleeding, pelvic 
pressure symptoms, infertility and growth or regress throughout the life. Leiomyoma 
affects millions of women and it is a leading cause of hysterectomy (5). Treatment 
includes medical therapy, surgical intervention, and uterine artery embolization or ablative 
techniques and depends on the patient's age, reason for treatment, concern of fertility 
preservation, and patient's preference (6-8). Some women do not want the traditional 
management of symptomatic fibroids such as surgery (hysterectomy or myomectomy) and 
wish to conserve their uterus and fertility (9). So, it seems that the side effect of less 
dangerous treatments and intervention should be considered. The nutrition role in the 
prevalence of leiomyoma was focused in some studies. Intake of dairy products, omega-3 
fatty acid, soybean milk, food additives and sweeteners increase the risk of leiomyoma, but 
high fruit intake may reduce the leiomyoma risk in black women (10-13). 
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Some studies have recently shown that vit D deficiency is 
an important risk factor for uterine fibroids (14-16) and 
uterine fibroids express lower levels of vit D receptor (VDR) 
compared with myometrium (17). Vit D deficiency is 10 
times more among African American women (40-45%) than 
the other people (4%) and also, leiomyoma in African 
American women is three times more prevalent than white 
women (18). As regards that the 1, 25(OH) 2D3 functions as 
a potent antiestrogen/antiprogesteronic agent, it may have 
utility as a novel therapeutic option for uterine fibroids (19). 
There is a high rate of vit D deficiency among women 
especially in Iran. In a study performed among 1210 males 
and females in Tehran (2004), the prevalence of deficiency 
(vit D <35 nmol/L) was 81.1%20. Also, the high prevalence 
of hypo vitaminosis D was detected in a research 
commenced among 5232 men and women in five large cities 
of Iran with different weather conditions (20, 21). 
Also, in vivo and in vitro studies showed that vitamin D 
inhibited the uterine fibroid growth as a potent anti-tumor 
agent (22, 23). According to the recommendations of the 
Endocrine Society, vit D status should be evaluated in 
patients with vit D deficiency (24) and in cases of vit D 
deficiency; 25-hydroxyvit D3 is more effective than sun 
exposure in increasing 25-hydroxyvitamin D3 (25). 
Since, there is a high prevalence of vit D deficiency in 
Iran and also, there are numbers of in vivo and vitro 
biological studies on the relationship of vit D and uterine 
leiomyomas (14-16, 26-28).  But the present data are 
insufficient to detect the role of vit D as a medical therapy 
for the treatment of uterine fibroids in humans, which would 
require a randomized controlled trial. So, we aimed to 
evaluate the effect of vit D supplementation on the size of 
uterine leiomyomas in Iranian women. 
 
 
Methods 
Study design and target group: This double-blind clinical 
trial was conducted in Obstetrics and Gynecology 
Department of Isfahan Alzahra and Shahid Beheshti 
Hospitals, Center of Iran from August 2014 to December 
2015. In this study, we used restricted randomization by 
random allocation rule and we used sequentially numbered, 
sealed, opaque envelope. These envelopes were prepared by 
main investigator and a trained midwife who selected an 
envelope for each patient was not aware of the content inside 
the envelope. Meanwhile, sonolgist who evaluated the size 
of myoma was not aware of patient's allocation. Finally, data 
analysis was conducted by a blind person, too (IRCT: 
20160521027998N5). 
 Based on randomized blocks with size 4; the first sample 
was assigned to group A, the second sample was included in 
group A, the third and the fourth samples were placed in 
group B, and such a random division continued in the 
following order until all 70 samples were divided. 
Healthcare therapists and staff as well as the subjects 
were not aware of the groups assigned and the trained 
midwife in the clinic was only given specific codes which 
were entirely blind. (AABB, ABBA, ABAB, BBAA, BABA, 
BAAB..a.). Since the women who had myoma with 20-80 
mm size were included in this study, we estimated the mean 
size of myoma will be about 50 mm. We estimated the size 
of myoma in vit D group that will be reduced by about 10 
mm. By considering 15 mm standard deviation, we 
calculated that 36 samples would be required in each group 
with a power of 80% and α=0.05. 
The leiomyoma size of patients receiving vit D 
(intervention group) was compared to patients in control 
group. Inclusion criteria consisted of patients referred to 
Obstetrics and Gynecology department of Alzahra and 
Shahid Beheshti hospitals with a diagnosis of leiomyomas, 
signed a consent form to participate in the study plus having 
the age between 35 -– 49 years, with 1 to 2 uterine 
leiomyomas size 20-80 mm and with serum levels of 25-
hydroxyvitamin D3 <20 ng/ml. Exclusion criteria consisted 
of age <35 years or >49 years, consuming hormonal drugs, 
massive vaginal bleeding, sonographic evaluation of the 
characteristics of the uterus is difficult or in the presence of 
suspected adenomyosis. Furthermore, patients reporting 
malignancy, hypertension, diabetes, multiple sclerosis, 
autoimmune disorders, and coronary, hepatic, or renal 
diseases, pregnancy, menopause, hormonal treatment 
(including oral contraceptive) during the past 3 months, vit D 
supplementation, and chronic assumption of medications, 
dissatisfaction to continue participation in study, improper 
use of vit D and losing to follow-up due to various causes. 
 The primary outcome included the size of the myoma 
and the level of vitamin D, and the secondary outcome 
including the symptoms of uterine myomas such as vaginal 
bleeding, pelvic pain, and urinary symptoms. 
Participants: The study flowchart is shown in figure 1. 
Seventy patients with a diagnosis of uterine leiomyomas, 
who had been diagnosed by obstetricians and based on 
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inclusion and exclusion criteria, were included. Leiomyomas 
were diagnosed with transvaginal and transabdominal 
ultrasound screening (transabdominal allows for 
visualization of pedunculated leiomyomas that are not likely 
to be seen transvaginal). Masses of 2-8 cm in diameter and 
larger qualified as leiomyomas. Experienced sonographers 
were trained on the study protocol and worked under the 
direct supervision of an expertise sonologist.  
Sampling was performed in specific season and the 
amount of daily activity and exposure to sunlight in 9-12 
every morning in both groups without the use of face and 
hand sunscreens during the sun exposure. 25-
hydroxyvitamin D3 levels were measured in all eligible 
patients before intervention and in those with levels less than 
20 ngr/ml (or 50 nmal/lit) were randomly divided into two 
groups using a block randomization procedure with matched 
subjects in each block based on daily activity and exposure 
to sunlight. Women were randomly assigned to receive 
vitamin D 50,000 IU every 2 weeks for 10 weeks (Iranian 
Zahravi Corp.) (n=35, Group A), while group B (n=35) 
received placebo consisting of exepian without vit D3 with  
the same color and shape (Zahravi co, Iran)  and were given  
in the same paper bags as blinded controls. All participants, 
investigators and staffs were blinded to the treatment 
assignment during the whole period of study. For assessing 
compliance, patients were requested to return unused 
capsules at the follow-up visit. We used stored plasma 
samples to measure the circulating metabolite, 25-
hydroxyvitamin D (25(OH) D), which is the accepted 
biomarker for vit D (19). Radioimmunoassay (RIA) for 
25(OH) D (20) was conducted by specific laboratory for all 
patients. Sixty-nine patients completed the study; 34 from 
intervention group and 35 from control group. The study 
received ethics approval from the Ethics Committee of 
Isfahan University of Medical Sciences (394453), and all 
participants gave written informed consent. At the end of the 
study, 25-hydroxyvitamin D3 levels were measured and 
intrauterine ultrasound was performed to evaluate uterine 
leiomyoma size with same operator and in same previous 
center 6 months later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study flowchart (CONSORT format) 
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Data analysis: Data were analyzed and reported only for 
patients who completed the trial. Statistical analysis of data 
was performed using SPSS Version 22 software. The normal 
distribution of all studied parameters was checked with 
Kolmogorov-Smirnov test and we found that the distribution 
of the outcome variable was normal. Student t-test and 
paired t-test were used for variables which were distributed 
in a normal way. The two tailed p-value less than 0.05 was 
considered significant. A p-value <0.05 was considered 
significant.  
 
 
Results 
Demographic features in terms of age (P=0.592), BMI 
(P=0.841) and age at menarche (P=0.731) in both groups 
were similar. As well, the physical activity (P=0.976) and 
sun light exposure (P=0.645) were similar (table 1). Three 
patients were dropped out (n=2, no criteria and n=1 lost to 
follow-up) and finally, 69 patients completed the study. 
Before the intervention, studied variables did not show 
significant differences between the groups. 25-
hydroxyvitamin D3 levels in intervention and placebo group 
were 16.82 ng/ml and 16.77 ng/ml, respectively (P=0.925) 
and the size of leiomyomas was 59.73 mm and 60.31 mm, 
respectively (P=0.847). As obtained, after a 10- week 
intervention, 25-hydroxyvitamin D3 levels were significantly 
higher in group receiving vit D as compared to placebo 
group (36.08 vs 16.25 ngr/ml) (P<0.001). Moreover, 
leiomyomas size significantly changed in vit D group. 
Leiomyomas, size in vit D group significantly decreased as 
compared to placebo group (52.58 vs 61.11 mm, 
respectively) (P=0.006), while by analyzing data with paired 
t test, the size of leiomyomas in control group did not change 
significantly (P=0.315). 
 
Table 1: Studied variables before and after intervention in both control and vitamin D groups 
Group 
Variables 
Vitamin D 
( group A) 
Control 
( group B) 
P-value 
Studied variables 6 months before  intervention in both control and vitamin D groups 
Age (year) 40.58±4.26 40.6±4.08 0.592 
BMI (kg/m2) 23.38±4.33 23.17±4.36 0.841 
Age at menarche (years) 11.55±1.94 11.4±1.88 0.731 
Sunlight exposure (min) 74.85±24.16 77.42±21.97 0.645 
25-hydroxyvitamin D3 levels (ng/ml) 16.82±2.22 16.77±2.32 0.925 
Leiomyoma size (mm) 59.73±13.51 60.31±11.3 0.847 
Studied variables 6 months after intervention in both control and vitamin D groups 
25-hydroxyvitamin D3 levels (ng/ml) 36.08±2.83 16.25±2.24 <0.001 
Leiomyoma size (mm) 52.58±13.72 61.11±11.16 0.006 
                                  * Independent T-Test 
Table 2: Mean differences in studied variables in intervention and control group  
Variables Mean SD 95% Confidence Interval of the Difference t df Sig. 
Lower Upper 
Mean differences in studied variables in intervention group 
25-hydroxyvitamin D3 levels (ng/ml) -19.26 3.85 -20.61 -17.91 -29.133 33 <0.001 
Leiomyomas size (mm) 7.14 3.86 5.79 8.49 10.79 33 <0.001 
Mean differences in studied variables in control group 
25-hydroxyvitamin D3 levels (ng/ml) -1.02 6.2 -3.06 1.01 -1.019 37 0.315 
Leiomyoma size (mm) -0.28 1.98 -0.94 0.36 -0.899 37 0.375 
   Paired T-test  
 
Discussion 
This study aimed to evaluate the effect of vitamin D 
supplementation on the size of uterine leiomyomas in Iranian  
 
women. Our results showed that vit D supplementation has 
significant effect on the size of leiomyomas in 
premenopausal women with vit D deficiency. In other words, 
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by the administration of vit D in patients in intervention 
group, the six of leiomyomas decreased by 7.14 mm. By 
comparing the size of leiomyomas between the groups (vit D 
and control), we observed significant reduction in 
intervention group. Besides, vit D administration increased 
the 25-hydroxyvitamin D3 levels obviously. In this regard, 
Halder SK et al. showed lower serum levels of either 25-
hydroxyvitamin D3 or 1, 25-dihydroxyvitamin D3, related to 
increase the risk of symptomatic uterine fibroids (23). 
 And also, in another study Halder SK et al, suggest that 
supplementation with the paricalcitol may be noninvasive 
medical treatment choice for uterine fibroids (29). Sharan C 
et al. and Bla¨uer M et al. have also recently reported that, 
25-dihydroxyvitamin D3 induced leiomyoma growth 
inhibition via catechol-omethyl transferase in vitro (30, 31). 
The results of Halder SK study demonstrated that 1; 25-
dihydroxyvitamin D3 treatment decreases the uterine 
leiomyoma tumor size in the Eker rat model (23). Most of 
the study demonstrated the effect of 1, 25-dihydroxyvitamin 
D3 on apoptosis, modulation of several cell growth genes, 
protein synthesis, and cell proliferation (23, 30-33).  These 
functions are the base of anti-tumor effect of   1, 25-
dihydroxyvitamin D3 on leiomyoma. Holder et al. in their 
study showed that estrogen and progesterone receptor on rat 
uterine leiomyoma cells reduced by receiving the 0.5 
microgram per Kg of 1, 25-dihydroxyvitamin D3(23).   
The  significant role of vit D3 deficiency  in the  uterine 
fibroid  development  resulted  from Soumia Brakta et al;s  
study in which vitamin D3 administration is an effective, 
safe, nonsurgical medical treatment option for the uterine 
fibroids  treatments (28) and  the  sufficient  dose  of vit D is 
associated with a reduced risk of uterine fibroids (29). The 
results of this study are consistent with to other in- vivo and 
in-vitro studies in which vit D reduces the frequency and the 
size of leiomyomas (14-16, 22, 23, 26-31,). Therefore, the 
administration of Vit D is a low cost and estimating a yearly 
cost of maintenance therapy in the vit D deficiency context   
is approximately $32 (34, 35,36).  
The limitations of this study were the small sample size 
and does not evaluate the effect of different levels of vit D3  
and estrogen and progesterone receptors, physical activity, 
smoking, parity on leiomyoma size, further studies with 
larger sample size, and as well as clinical trial studies are 
recommended. Furthermore, as the study was conducted in 
Asian women, it may not be applicable in women with other 
ethnicities. In addition, the exact mechanism for these 
findings needs to be further investigated to be able to explain 
the mechanism of the reduction of leiomyoma tumor in 
humans. 
In conclusion, the present results showed that vit D 
administration reduces the size of uterine myoma, and no 
case of toxicity was observed.  It seems that vit D 
administration is the effective way to treat leiomyoma.  
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